The Team
| Dr Anthony
(Tony) C Nicholls, Chief Executive Officer and Director has
over 30 years experience in the development and marketing of medical
devices and diagnostics. He has, throughout his career, been associated
with the successful commercial introduction of new technology, inter
alia, enzyme immunoassay, monoclonal antibody cell culture, serological
testing for tuberculosis, HIV, HTLV and Lyme disease, random access
clinical chemistry, endoluminal culture of central venous catheters
and saliva-based testing for HIV. He was a founder of FAS Medical
Ltd., Trinity Biotech plc and Cambridge Biotech Corp. and has been
the principal executive officer in a number of IPO, secondary public
offerings and Private Placement Offerings in the USA, Canada and the
UK. Tony’s academic career included seven years as Head of Microbiology
and Immunology at the Midhurst Medical Research Institute in Sussex,
England, and he is the author of several scientific papers and patents.
|
 |
| C Dawson Buck,
Non-Executive Chairman has over thirty years
top level management experience in both companies he has created and
multinational corporations. Initially a graduate trainee with Unilever,
he was Group Chief Executive of Automated Security Holdings from 1974
to 1992. Since then Dawson has been President of Sensormatic Electronic
International, CEO and Secretary General of the British Equestrian
Federation and Deputy Chief executive of Angle plc, an international,
consulting, management and venturing company focusing on the commercialization
of technology. He is currently a Non-Executive Director of Corpora
plc and Non-Executive Chairman of Provexis plc |
 |
| Henry Hyde-Thomson,
Director and acting CFO is the Chairman
of Anglo Scientific, a private equity firm specialising in start-ups.
Henry is on the board of three other Anglo Scientific companies: 21Net,
the Broadband to Trains service provider, Phasor Solutions which is
developing ASICs for phased arrays and MMIC Solutions, which is making
very high frequency multi-chip modules. Previously Henry was the founder
and Chairman of Speech Machines, the developer of Internet based speech
recognition systems acquired by Philips in April 2001. Henry has 5
patents and over 25 years experience of high technology business.
He graduated from Oxford University with first-class honours in Physics,
and after two years research in astrophysics then qualified as a Chartered
Accountant with Peat Marwick Mitchell. |
 |
| Dr Mark Hudson,
Operations Director, received his doctorate
in 1992 in Biochemistry from Manchester University. Mark held two
senior research positions in Clinical Oncology at Imperial College
London and The Imperial Cancer Research Fund before joining Prolifix
Ltd in 2000, where he managed the design and development of cancer
drug screening programmes and an international collaborative venture
with Eli Lilly and Chugai Pharmaceuticals. In June 2002, he became
the Head of Manufacturing at Proimmune Ltd, where he radically improved
the company’s production process, resulting in a doubling of
product output. He was also responsible for bringing two new products
to market. In 2004 Mark was invited into The Daresbury Laboratories
as a ‘Visiting Entrepreneur’, to develop and commercialise
a novel diagnostic system. During this time and to date, he joined
L3 Technology as Operations Director, where he has established and
manages the Company’s new research facilities. In this role
he has also made significant scientific contributions to the development
of a rapid Point of Care lipid-profiling device. |
 |